Tibsovo

Description

Tibsovo is an oral medication taken once daily that targets a specific gene mutation called isocitrate dehydrogenase-1 (IDH1) mutation that can affect bone marrow. The IDH1 mutation prevents young blood cells from developing into healthy adult blood cells, which can lead to blood and bone marrow diseases such as acute myeloid leukemia (AML).

Tibsovo can be used to treat adults with confirmed disease. susceptible IDH1 mutation in:

– newly diagnosed acute myeloid leukemia (AML), either in combination with azacitidine or as monotherapy in patients 75 years of age and older who have comorbidities that prevent the use of intensive induction chemotherapy

– relapsed or refractory AML

– relapsed or refractory myelodysplastic syndrome

– bile duct cancer (cholangiocarcinoma) that has progressed or spread to other parts of the body (metastatic) after treatment with other drugs.

Tibsovo targets the IDH1 mutation. In normal cells, the IDH1 gene produces a protein called IDH1, which is involved in normal cellular chemical processes. However, when the IDH1 gene is modified due to a genetic mutation, it results in an abnormal version of the IDH1 protein and other substances, such as the oncometabolite, D-2-hydroxyglutarate (2-HG). Tibsovo lowers 2-HG levels by decreasing the number of blasts and increasing the number of mature myeloid cells. Blasts are immature cells in the bone marrow that will later mature into red blood cells, white blood cells, or platelets, which clot the blood. They are not normally found in the bloodstream, and their presence signals problems with the bone marrow, such as myelodysplastic syndrome.

Active ingredient: ivosidenib

Prescription drug

The drug is shipped from Germany